Recently, the U.S. Food and Drug Administration announced that they are looking to make improvements to the way they oversee mammography services, and the information communicated to patients. The goal is to provide patients with all necessary information, so that they may be empowered when considering important decisions regarding their breast health care.
“Mammograms of dense breasts—breasts with a higher proportion of fibroglandular tissue compared to fatty tissue—can be difficult to interpret because the dense tissue can obscure signs of breast cancer and lower the sensitivity of the image. Dense breasts have also been identified as a risk factor for developing breast cancer.” –FDA News Release, March 27th, 2019
As the FDA considers new policies regarding the oversight of mammography services and breast density reporting, you can rest assured knowing Vancouver Radiologists is ahead of the curve. Our Genius 3D mammography exams are FDA approved as superior for women with dense breasts.1-2 For more information on breast density, check out our Breast Density Breakdown, or schedule your appointment today.
1Results from Friedewald, SM, et al. “Breast cancer screening using tomosynthesis in combination with digital mammography.” JAMA 311.24 (2014): 2499-2507; a multi-site (13), non randomized, historical control study of 454,000 screening mammograms investigating the initial impact of the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ Mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
2FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005. 7. Raerty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.